ImageneBio stock analysis
Want to see IMA full AI Analyst Report?
ImageneBio (IMA) Stock Price & Analysis
IMA Stock Chart & Stats
- Day’s Range
- $3.34 - $3.58
- 52-Week Range
- $3.34 - $8.32
- Previous Close
- $3.45
- Volume
- N/A
- Average Volume (3M)
- 12.27K
- Market Cap
- $43.22M
- Enterprise Value
- -$41.38M
- Total Cash (Recent Filing)
- $126.60M
- Total Debt (Recent Filing)
- $6.79M
- Price to Earnings (P/E)
- ―
- Beta
- 0.91
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Debt of just $1.3M against $128.1M of equity gives the company a low leverage burden for an early-stage biotech. This reduces near-term solvency pressure and preserves greater flexibility to fund clinical development while it remains pre-commercial.
Meaningful Capital Base
The $142.5M asset base and $128.1M of equity provide a substantial financial foundation relative to the company’s modest debt. That capital base can support ongoing research and development and offers more resilience than a highly leveraged balance sheet.
Reduced Losses
Net losses have improved from roughly $68M in 2022–2023 to $43.3M on a TTM basis, suggesting some cost moderation. Although the company remains unprofitable, this improvement could help extend financial resources if maintained through future development periods.
Bears Say
No Meaningful Revenue
Revenue has declined to zero on a TTM basis, confirming that ImageneBio has not established meaningful operating scale or recurring commercial sales. This leaves the business dependent on successful clinical progress and future financing or partnering to support its operations.
Persistent Large Losses
Large ongoing net losses show that the company remains far from breakeven as a pre-commercial biotech. Continued losses reduce retained capital, limit self-funded investment capacity, and make future financial performance highly dependent on advancing candidates toward commercial value.
Sustained Cash Burn
Persistent negative free cash flow demonstrates that operations consume substantial cash rather than funding themselves. The company therefore remains dependent on external funding, while volatile burn and a 29.7% TTM decline versus the prior annual period increase planning and financing pressure.
ImageneBio News
IMA FAQ
What was ImageneBio’s price range in the past 12 months?
What is ImageneBio’s market cap?
When is ImageneBio’s upcoming earnings report date?
How were ImageneBio’s earnings last quarter?
Is ImageneBio overvalued?
Does ImageneBio pay dividends?
What is ImageneBio’s EPS estimate?
How many shares outstanding does ImageneBio have?
What happened to ImageneBio’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ImageneBio?
What is the TipRanks Smart Score and how is it calculated?
ImageneBio Stock Smart Score
Company Description
ImageneBio
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kristin Yarema
- Employees
- 18
- Website
- www.inmagenebio.com
- Address
- 12526 High Bluff Drive, Suite 345, San Diego, CA 92130, San Diego, CA, 92130, US
ImageneBio (IMA) Earnings & Revenues
IMA Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |














